KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Non-Current Liabilities: 2012-2025

Historic Other Non-Current Liabilities for TherapeuticsMD (TXMD) over the last 5 years, with Sep 2025 value amounting to $871,000.

  • TherapeuticsMD's Other Non-Current Liabilities rose 23.55% to $871,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $871,000, marking a year-over-year increase of 23.55%. This contributed to the annual value of $744,000 for FY2024, which is 16.98% up from last year.
  • As of Q3 2025, TherapeuticsMD's Other Non-Current Liabilities stood at $871,000, which was up 4.69% from $832,000 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Other Non-Current Liabilities ranged from a high of $2.1 million in Q4 2021 and a low of $358,000 during Q2 2021.
  • Over the past 3 years, TherapeuticsMD's median Other Non-Current Liabilities value was $795,000 (recorded in 2025), while the average stood at $849,182.
  • As far as peak fluctuations go, TherapeuticsMD's Other Non-Current Liabilities skyrocketed by 2,065.71% in 2021, and later tumbled by 48.25% in 2022.
  • TherapeuticsMD's Other Non-Current Liabilities (Quarterly) stood at $2.1 million in 2021, then tumbled by 48.25% to $1.1 million in 2022, then slumped by 42.55% to $636,000 in 2023, then grew by 16.98% to $744,000 in 2024, then rose by 23.55% to $871,000 in 2025.
  • Its Other Non-Current Liabilities was $871,000 in Q3 2025, compared to $832,000 in Q2 2025 and $795,000 in Q1 2025.